最近，ITM Isotope Technologies公司发布了好消息：其创新的靶向放射性疗法ITM-11在针对无法手术切除的进展性胃肠胰神经内分泌肿瘤（GEP-NETs）患者的3期临床试验COMPETE中取得了令人瞩目的结果。该研究表明，ITM-11在延长患者的无进展生存期（PFS）方面，展现出了优于常规靶向治疗药物的显著成效。 COMPETE试验采用的设计为前瞻性、随机和含活性对照的开放标签研 ...

RBC Capital analyst Erwan Kerouredan reiterated a Buy rating on ITM Power (ITM – Research Report) on January 31 and set a price target of ...

COMPETE是一项前瞻性、随机、含活性对照、开放标签的3期临床试验，旨在评估ITM-11与依维莫司（everolimus）这一标准治疗方案相比的疗效和安全性。ITM-11由镥177（一种发射β射线的放射性同位素）和edotreotide组成。Edo ...

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...

ITM Power PLC (ITMPF) reports significant revenue increase and operational improvements, while navigating market challenges ...

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.

ITM Radiopharma has announced that its Phase III trial examining its gastroenteropancreatic tumour treatment, ITM-11, met its ...

Investors in ITM Power Plc (LON:ITM) had a good week, as its shares rose 4.4% to close at UK£0.37 following the release of its half-year results. Revenues were in line with expectations, at UK£16m, ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

ITM Universe Gwalior successfully organized Synergy 2.0, a flagship event themed "Where HR Leaders Connect and Inspire." This impactful event brought together HR professionals, industry leaders, and ...

Constantin Hesse, an analyst from Jefferies, maintained the Buy rating on ITM Power (ITM – Research Report). The associated price target ...